Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. All-cause and cause-specific mortality in microscopic colitis: a Danish nationwide matched cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Salivary microbiota and inflammation-related proteins in patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Single nucleotide polymorphisms (SNPs) in TNF receptor superfamily (TNFRSF) 1A and 1B, and Fas ligand (FASLG) genes, have been associated with responsiveness to infliximab (IFX) in Crohn's disease.
Original languageEnglish
JournalAlimentary Pharmacology and Therapeutics
Volume36
Issue number7
Pages (from-to)650-9
Number of pages10
ISSN0269-2813
DOIs
Publication statusPublished - 2012

ID: 36603496